We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints
Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints
September 18, 2012
Jennerex has announced positive clinical data from Phase II trial of JX594, a proprietary, engineered oncolytic immunotherapy, in sorafenib-refractory hepatocellular carcinoma (liver cancer, HCC) patients. Pharmaceutical Business Review
